Alon Lazarus

Alon Lazarus formerly worked at Reunion Neuroscience, Inc., as Director, Pantheon Biosciences Ltd., as Director, Oncorus, Inc., as Director from 2016 to 2019, Keros Therapeutics, Inc., as Independent Director from 2016 to 2020, Quiet Therapeutics Ltd., as Director, Entact Bio Ltd., as Director from 2019 to 2023, Auron Therapeutics, Inc., as Director, Lutris Pharma Ltd., as Director, Werewolf Therapeutics, Inc., as Independent Director from 2019 to 2024, Photys Therapeutics, Inc., as Director, Paros Bio, Inc., as Director, Entact Bio, Inc., as Director, Integra Holdings Ltd., as Analyst, Yissum Holdings Ltd., as Head-Business Development from 2012 to 2013, Arkin Bio Ventures, as Biotech Investment Manager from 2013 to 2024, and Arkin Capital, as Manager-Biotech Investment.
Dr. Lazarus received his doctorate degree from The Hebrew University Hadassah Medical School and undergraduate degree and Masters Business Admin degree from The Hebrew University of Jerusalem.